89bio Yönetim
Yönetim kriter kontrolleri 2/4
89bio's CEO is Rohan Palekar, appointed in Jul 2018, has a tenure of 6.33 years. total yearly compensation is $5.59M, comprised of 10.9% salary and 89.1% bonuses, including company stock and options. directly owns 0.27% of the company’s shares, worth $2.60M. The average tenure of the management team and the board of directors is 3.3 years and 4.3 years respectively.
Anahtar bilgiler
Rohan Palekar
İcra Kurulu Başkanı
US$5.6m
Toplam tazminat
CEO maaş yüzdesi | 10.9% |
CEO görev süresi | 6.3yrs |
CEO sahipliği | 0.3% |
Yönetim ortalama görev süresi | 3.3yrs |
Yönetim Kurulu ortalama görev süresi | 4.3yrs |
Son yönetim güncellemeleri
Recent updates
89bio: Surviving A Competitive Space - For Now
Oct 29Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?
Sep 2689bio: Bullish In Light Of Further MOA Being Established By Peer
Aug 0789bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy
May 2389bio Still Has A Chance As NASH Race Heats Up
Oct 0689bio completes enrollment in phase 2 trial for NASH treatment
Aug 1889Bio rallies on Deep Track Capital disclosing 10% stake
Jul 0789bio: Undervalued Contender In Race For First NASH Drug Approval
Jul 20We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely
May 0789bio: NASH Drug Developer With Differentiated Profile
Jan 29We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely
Jan 2289bio expects to initiate Phase 2b NASH trial in 1H21
Jan 05CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$175m |
Mar 31 2024 | n/a | n/a | -US$165m |
Dec 31 2023 | US$6m | US$611k | -US$142m |
Sep 30 2023 | n/a | n/a | -US$127m |
Jun 30 2023 | n/a | n/a | -US$119m |
Mar 31 2023 | n/a | n/a | -US$105m |
Dec 31 2022 | US$3m | US$588k | -US$102m |
Sep 30 2022 | n/a | n/a | -US$104m |
Jun 30 2022 | n/a | n/a | -US$105m |
Mar 31 2022 | n/a | n/a | -US$101m |
Dec 31 2021 | US$5m | US$565k | -US$90m |
Sep 30 2021 | n/a | n/a | -US$76m |
Jun 30 2021 | n/a | n/a | -US$63m |
Mar 31 2021 | n/a | n/a | -US$54m |
Dec 31 2020 | US$5m | US$530k | -US$49m |
Sep 30 2020 | n/a | n/a | -US$56m |
Jun 30 2020 | n/a | n/a | -US$60m |
Mar 31 2020 | n/a | n/a | -US$64m |
Dec 31 2019 | US$1m | US$431k | -US$57m |
Sep 30 2019 | n/a | n/a | -US$44m |
Jun 30 2019 | n/a | n/a | -US$30m |
Dec 31 2018 | US$708k | US$195k | -US$18m |
Tazminat ve Piyasa: Rohan's total compensation ($USD5.59M) is above average for companies of similar size in the US market ($USD3.24M).
Tazminat ve Kazançlar: Rohan's compensation has increased whilst the company is unprofitable.
CEO
Rohan Palekar (58 yo)
6.3yrs
Görev süresi
US$5,587,661
Tazminat
Mr. Rohan Palekar serves as the Chief Executive Officer and Director at 89bio, Inc. since July 16, 2018. He is an Independent Director at Neoleukin Therapeutics, Inc since March 02, 2022 and Neurogene Inc....
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO & Director | 6.3yrs | US$5.59m | 0.27% $ 2.6m | |
Chief Technical Officer | 5.7yrs | US$2.51m | 0.15% $ 1.4m | |
Chief Medical Officer | 5.9yrs | US$2.54m | 0.088% $ 854.6k | |
Chief Financial Officer | 5.3yrs | Veri yok | 0.042% $ 409.8k | |
Chief Operating Officer | less than a year | Veri yok | Veri yok | |
Senior Vice President of Finance & Principal Accounting Officer | no data | Veri yok | Veri yok | |
VP of Investor Relations & Corporate Communications | less than a year | Veri yok | Veri yok | |
Vice President of People & Culture | 3.8yrs | Veri yok | Veri yok | |
Senior Vice President of Commercial Strategy | no data | Veri yok | Veri yok | |
Senior Vice President of R&D Operations | 2.8yrs | Veri yok | Veri yok | |
Senior VP & Head of Quality | 1.8yrs | Veri yok | Veri yok | |
Chief Regulatory & Quality Officer | less than a year | Veri yok | Veri yok |
3.3yrs
Ortalama Görev Süresi
57yo
Ortalama Yaş
Deneyimli Yönetim: ETNB's management team is considered experienced (3.3 years average tenure).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO & Director | 6.3yrs | US$5.59m | 0.27% $ 2.6m | |
Independent Director | 3yrs | US$360.17k | 0% $ 0 | |
Independent Director | 4.3yrs | US$363.33k | 0% $ 0 | |
Independent Director | 6.6yrs | US$358.33k | 0.23% $ 2.3m | |
Independent Director | less than a year | Veri yok | Veri yok | |
Independent Chairman of the Board | 4.7yrs | US$385.83k | 0% $ 0 | |
Director | less than a year | Veri yok | Veri yok | |
Independent Director | 2.8yrs | US$354.60k | 0% $ 0 | |
Independent Director | 6.6yrs | US$352.33k | 0% $ 0 |
4.3yrs
Ortalama Görev Süresi
62yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ETNB's board of directors are considered experienced (4.3 years average tenure).